NCT00002049已完成不适用
Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
Immunobiology Research Institute2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings of patients infected with HIV who do not yet have AIDS.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Aerosolized pentamidine.
- •Patients must have the following:
- •- Seropositive for HIV-1 (ELISA assay) confirmed by Western blot. HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patients' peripheral blood monocytes (PBMC) on two separate occasions. Voluntarily sign consent.
- •Patients with HIV "wasting syndrome" are included.
- •Prior Medication:
- •Aerosolized pentamidine.
排除标准
- •Co-existing Condition:
- •Patients with the following are excluded:
- •AIDS as defined by the CDC (except for those with HIV "wasting syndrome").
- •Significant hepatic disease.
- •Thrombocytopenia.
- •Hypersensitivity to thymopentin.
- •Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
- •Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.
- •Patients with the following are excluded:
- •AIDS as defined by the CDC (except for those with HIV "wasting syndrome").
- •Significant hepatic disease.
- •Thrombocytopenia.
- •Hypersensitivity to thymopentin.
- •Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
- •Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.
- •Prior Medication:
- •Excluded within 30 days of study entry:
- •Immunomodulatory or experimental therapy.
- •Excluded within 90 days of study entry:
- •Zidovudine (AZT).
- •Intravenous drug abuse.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected PatientsHIV InfectionsNCT00002289Immunobiology Research Institute
已完成
不适用
A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected PatientsHIV InfectionsNCT00002050Immunobiology Research Institute
已完成
不适用
Double Blind Study of Thymopentin Effects on Patients With HIV-1 InfectionHIV InfectionsNCT00002066Immunobiology Research Institute
已完成
不适用
Double Blind Study of Thymopentin Effects on Patients With HIV-1 InfectionHIV InfectionsNCT00002051Immunobiology Research Institute
已完成
2 期
A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV DrugsHIV InfectionsNCT00002332Immunobiology Research Institute60